Oruka Therapeutics disclosed Phase 2 psoriasis data for its long-acting injectable candidate, ORKA-001, with 63% of patients achieving complete skin clearance in a mid-stage readout. The company also reported an updated exposure analysis supporting dosing as infrequently as once per year. Oruka’s goal is to position the therapy as a potential alternative to established IL-23/IL-17/IL-12/23 pathways represented by commercial blockbusters such as Skyrizi. Oruka still needs late-stage trials, but the company said the mid-stage results back its remission and reduced-injection strategy. Jefferies analysts highlighted the competitive angle, while Oruka’s next steps will focus on confirmatory studies and durability endpoints to validate the annual-dosing concept.